Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
"Characterization of adverse events, health care resource utilization, and real-world survival outcomes with introduction of ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in BC"
FY 2019-20
Summary
"Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in western countries. A particular drug that has proven to be very effective in newly diagnosed CLL patients and those who have relapsed is ibrutinib. Ibrutinib, however, causes certain side effects which can lead to early discontinuation of treatment and worse outcomes for patients. Most of what we know regarding the side effects of ibrutinib comes from clinical trials, which only accept healthy patients with few other medical problems. Little is known about how patients tolerate ibrutinib in the ""real-world"". It is therefore important that we obtain information from real-world practice, as clinical studies often underestimate discontinuation and survival rates. The goal of this study is to determine the frequency of side effects associated with ibrutinib compared to standard therapy using provincial administrative data obtained through PopData BC. Additionally, we aim to assess the impact of ibrutinib dose interruptions and reductions on survival outcomes, as well as the impact and cost of the side effects of therapy on the public health care system. A population based study will be completed comparing two groups of CLL patients: those receiving ibrutinib for treatment and those receiving an alternate therapy during the same time period. Both groups will be matched based on age, sex, line of therapy and predisposing factors related to the side effects of interest, to ensure the groups are comparable. Results from our study will provide important information to patients and health care providers regarding real-world risks of ibrutinib therapy and to governments and jurisdictions considering funding implications for ibrutinib on a population-basis. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428899
Name
Khelifi Rania
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
"Characterization of adverse events, health care resource utilization, and real-world survival outcomes with introduction of ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in BC"
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Events; Chronic Lymphocytic Leukemia; Clincal Practice; Health Care Resource Utilization; Ibrutinib; Outcomes Research; Population-Level; Real-World; Retrospective; Toxicity
Abstract
"Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in western countries. A particular drug that has proven to be very effective in newly diagnosed CLL patients and those who have relapsed is ibrutinib. Ibrutinib, however, causes certain side effects which can lead to early discontinuation of treatment and worse outcomes for patients. Most of what we know regarding the side effects of ibrutinib comes from clinical trials, which only accept healthy patients with few other medical problems. Little is known about how patients tolerate ibrutinib in the ""real-world"". It is therefore important that we obtain information from real-world practice, as clinical studies often underestimate discontinuation and survival rates. The goal of this study is to determine the frequency of side effects associated with ibrutinib compared to standard therapy using provincial administrative data obtained through PopData BC. Additionally, we aim to assess the impact of ibrutinib dose interruptions and reductions on survival outcomes, as well as the impact and cost of the side effects of therapy on the public health care system. A population based study will be completed comparing two groups of CLL patients: those receiving ibrutinib for treatment and those receiving an alternate therapy during the same time period. Both groups will be matched based on age, sex, line of therapy and predisposing factors related to the side effects of interest, to ensure the groups are comparable. Results from our study will provide important information to patients and health care providers regarding real-world risks of ibrutinib therapy and to governments and jurisdictions considering funding implications for ibrutinib on a population-basis. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khelifi, Rania
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~